Literature DB >> 7510070

Fludarabine phosphate: a new active agent in hematologic malignancies.

M J Keating1, S O'Brien, W Plunkett, L E Robertson, V Gandhi, E Estey, M Dimopoulos, F Cabanillas, A Kemena, H Kantarjian.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1994        PMID： 7510070

Source DB:  PubMed          Journal:  Semin Hematol        ISSN： 0037-1963            Impact factor:   3.851


× No keyword cloud information.
  4 in total

1.  Successful treatment of IgM paraproteinaemic neuropathy with fludarabine.

Authors:  H C Wilson; M P Lunn; S Schey; R A Hughes
Journal:  J Neurol Neurosurg Psychiatry       Date:  1999-05       Impact factor: 10.154

Review 2.  Inhibitors of the Cancer Target Ribonucleotide Reductase, Past and Present.

Authors:  Sarah E Huff; Jordan M Winter; Chris G Dealwis
Journal:  Biomolecules       Date:  2022-06-10

Review 3.  Clinical pharmacology and clinical trials of ribonucleotide reductase inhibitors: is it a viable cancer therapy?

Authors:  Mukundan Baskar Mannargudi; Subrata Deb
Journal:  J Cancer Res Clin Oncol       Date:  2017-06-17       Impact factor: 4.322

4.  Hepatitis B Reactivation in a HBsAg-Negative, HBcAb-Positive Patient Receiving Fludarabine for the Treatment of Chronic Lymphocytic Leukaemia.

Authors:  Federica Toscanini; Pasqualina De Leo; Giuseppe Calcagno; Federica Malfatti; Alessandro Grasso; Marco Anselmo
Journal:  Case Reports Hepatol       Date:  2011-06-15
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.